X4 PHARMACEUTICALS, INC (XFOR) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 99.15M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 99.15M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 99.15M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 99.15M | (m) | (m) |
| 2026-03-31 | 94.32M | (m) | (m) |
| 2025-12-31 | 90.92M | (m) | (m) |
| 2025-09-30 | 87.44M | (m) | (m) |
| 2025-06-30 | 11.41M | (m) | (m) |
| 2025-03-31 | 5.79M | (m) | (m) |
| 2024-09-30 | 170.55M | (m) | (m) |
| 2024-06-30 | 168.50M | (m) | (m) |
| 2024-03-31 | 167.94M | (m) | (m) |
| 2023-09-30 | 167.29M | (m) | (m) |
| 2023-06-30 | 164.42M | (m) | (m) |
| 2023-03-31 | 122.21M | (m) | (m) |
| 2022-12-31 | 122.21M | (m) | (m) |
| 2022-09-30 | 69.24M | (m) | (m) |
| 2022-06-30 | 68.65M | (m) | (m) |
| 2022-03-31 | 30.82M | (m) | (m) |
| 2021-12-31 | 30.81M | (m) | (m) |
| 2021-09-30 | 24.71M | (m) | (m) |
| 2021-06-30 | 24.85M | (m) | (m) |
| 2021-03-31 | 23.66M | (m) | (m) |
| 2020-12-31 | 17.38M | (m) | (m) |
| 2020-09-30 | 16.29M | (m) | (m) |
| 2020-06-30 | 16.18M | (m) | (m) |
| 2020-03-31 | 16.14M | (m) | (m) |
| 2019-12-31 | 16.13M | (m) | (m) |
| 2019-09-30 | 12.46M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |